Human T cell lymphotropic virus-associated leukemia/lymphoma.
OBJECTIVE
This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options.


RESULTS
New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition.


CONCLUSIONS
Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
Ratner
Lee
L
Division of Molecular Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO 63110, USA. lratner@im.wustl.edu
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000906:Antibodies / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015480:Deltaretrovirus Antibodies / Q000627:therapeutic use; D015368:Human T-lymphotropic virus 1 / Q000472:pathogenicity*; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000503:physiopathology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000503:physiopathology*; D011379:Prognosis; D033581:Stem Cell Transplantation
D044966:Anti-Retroviral Agents; D000906:Antibodies; D000970:Antineoplastic Agents; D015480:Deltaretrovirus Antibodies